全球朊病毒疾病治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計朊病毒疾病治療市場將從 2025 年的 49 億美元成長到 2034 年的 78.2 億美元，2026 年至 2034 年的複合年成長率為 5.33%。

全球朊病毒病治療市場規模相對小規模，但由於朊病毒相關神經系統疾病的致命性和進行性，這個市場至關重要。例如，庫賈氏病等疾病儘管根治性治療方法有限，但仍需要專業的醫療管理。神經科對朊病毒病的認知不斷提高，以及診斷影像和腦脊髓液檢測技術的進步，正推動著早期檢出率的提升。此外，罕見疾病和孤兒疾病研究經費的增加也促進了市場的發展。目前，支持性治療和實驗性治療方法在朊病毒病治療領域佔據主導地位。

研究機構和生技公司正積極探索針對異常朊病毒蛋白累積的疾病修正治療。分子生物學和神經退化性疾病研究的進展正在開闢新的研究途徑。已開發國家政府為孤兒藥提供優先待遇，以促進罕見疾病治療領域的創新。改進的監測系統正在加強病例識別和流行病學追蹤。合作研究舉措進一步推動了該領域的科學進步。

未來市場成長將主要取決於標靶治療和早期診斷工具的突破性進展。對精準醫療和生物標記開發的日益重視有望加速治療創新。擴大臨床試驗和國際研究合作可望增進我們對朊病毒疾病發病機制的理解。儘管患者數量仍然較少，但巨大的未滿足需求將繼續推動投資。隨著科學進步不斷改善治療方案，市場預計將穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球朊病毒疾病治療市場：依類型分類

• 市場分析、洞察與預測
• 庫賈氏病（CJD）
• 變異型庫賈氏病(vCJD)
• 變異型蛋白酶敏感朊病毒病
• 格斯特曼-施特勞斯勒-沙因克病
• 其他

第5章：全球朊病毒疾病治療市場：依藥物分類

• 市場分析、洞察與預測
• 抗憂鬱症
• 抗精神病藥物
• 其他

第6章：全球朊病毒疾病治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射

第7章 全球朊病毒疾病治療市場：依最終使用者分類

• 市場分析、洞察與預測
• 醫院
• 居家照護
• 專科診所
• 其他

第8章 全球朊病毒疾病治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific Inc
  • Illumina Inc
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche Ltd
  • Oncocyte Corporation
  • Johnson & Johnson Services Inc
  • PathAI Inc
  • Guardant Health
  • Labcorp
  • Sysmex Inostics Inc
  • Sangamo Therapeutics Inc
  • Voyager Therapeutics Inc
  • Merck & Co. Inc
  • Genentech Inc

The Prion Disease Treatment Market size is expected to reach USD 7.82 Billion in 2034 from USD 4.90 Billion (2025) growing at a CAGR of 5.33% during 2026-2034.

The Global Prion Disease Treatment Market is relatively niche but critically important due to the fatal and progressive nature of prion-related neurological disorders. Conditions such as Creutzfeldt-Jakob disease require specialized medical management, even though effective curative therapies remain limited. Growing awareness among neurologists and advancements in diagnostic imaging and cerebrospinal fluid testing are improving early detection rates. Increased research funding for rare and orphan diseases is also contributing to market development. Supportive care and experimental therapeutic approaches currently dominate the treatment landscape.

Research institutions and biotechnology companies are actively exploring disease-modifying therapies targeting abnormal prion protein accumulation. Advances in molecular biology and neurodegenerative disease research are opening new investigative pathways. Governments in developed countries are offering orphan drug incentives, encouraging innovation in rare disease therapeutics. Improved surveillance systems are strengthening case identification and epidemiological tracking. Collaborative research initiatives are further supporting scientific progress in this field.

Looking ahead, the market's future growth depends largely on breakthroughs in targeted therapies and early diagnostic tools. Increasing focus on precision medicine and biomarker development may accelerate treatment innovation. Expanded clinical trials and global research partnerships are expected to enhance understanding of prion pathogenesis. Although patient numbers remain small, high unmet medical need will continue to drive investment. The market is projected to grow steadily as scientific advancements improve therapeutic possibilities.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Types

• Creutzfeldt-Jakob Disease (CJD)
• Variant Creutzfeldt-Jakob Disease (CJD)
• Variably Protease-Sensitive Prionopathy
• Gerstmann-Straussler-Scheinker Disease
• Others

By Drug

• Antidepressant
• Antipsychotic Agents
• Others

By Route of Administration

• Oral
• Injectable

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Illumina Inc, BioRad Laboratories Inc, F HoffmannLa Roche Ltd, Oncocyte Corporation, Johnson Johnson Services Inc, PathAI Inc, Guardant Health, Labcorp, Sysmex Inostics Inc, Sangamo Therapeutics Inc, Voyager Therapeutics Inc, Merck Co Inc, Genentech Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PRION DISEASE TREATMENT MARKET: BY TYPES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Types
• 4.2. Creutzfeldt-Jakob Disease (CJD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Variant Creutzfeldt-Jakob Disease (CJD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Variably Protease-Sensitive Prionopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Gerstmann-Straussler-Scheinker Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRION DISEASE TREATMENT MARKET: BY DRUG 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug
• 5.2. Antidepressant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Antipsychotic Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRION DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PRION DISEASE TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PRION DISEASE TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Types
  • 8.2.2 By Drug
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Types
  • 8.3.2 By Drug
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Types
  • 8.4.2 By Drug
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Types
  • 8.5.2 By Drug
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Types
  • 8.6.2 By Drug
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PRION DISEASE TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific Inc
  • 10.2.2 Illumina Inc
  • 10.2.3 Bio-Rad Laboratories Inc
  • 10.2.4 F. Hoffmann-La Roche Ltd
  • 10.2.5 Oncocyte Corporation
  • 10.2.6 Johnson & Johnson Services Inc
  • 10.2.7 PathAI Inc
  • 10.2.8 Guardant Health
  • 10.2.9 Labcorp
  • 10.2.10 Sysmex Inostics Inc
  • 10.2.11 Sangamo Therapeutics Inc
  • 10.2.12 Voyager Therapeutics Inc
  • 10.2.13 Merck & Co. Inc
  • 10.2.14 Genentech Inc